Loading company…
Shanghai-based developer of therapies for chronic liver diseases, including NASH and chronic hepatitis B.
Founded in 2016 and headquartered in Shanghai, China, Yachuang Medicine develops treatments for chronic liver diseases, including Non-alcoholic Steatohepatitis (NASH) and Chronic Hepatitis B Infection (HBV). Through its subsidiary Hepagene Therapeutics, Inc., its lead candidate HPG1860 is in Phase I clinical trials for NASH. In April 2021 the company raised USD 40.00 mn in Series B funding led by Loyal Valley Capital, with Apricot Capital and Oceanpine Capital also investing.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in